摘要
目的探讨恩替卡韦与替诺福韦治疗乙型病毒性肝炎效果及对肾功能的影响。方法选取2017年2月至2019年12月于湛江中心人民医院诊治的慢性乙型病毒性肝炎患者50例作为研究对象,依据治疗方式不同分为恩替卡韦(ETV)组与替诺福韦(TDF)组,每组25例。比较两组患者天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、乙型肝炎病毒(HBV)-DNA转阴率、血肌酐(Scr)、估算肾小球滤过率(e GFR)、β_(2)-微球蛋白(β_(2)-MG)。结果在治疗第6个月TDF组患者AST、ALT低于ETV组,β_(2)-MG水平在治疗第3个月、第6个月高于ETV组,差异有统计学意义(P<0.05),治疗后第3、6、12个月两组患者HBV-DNA转阴率、RBP水平比较差异无统计学意义(P>0.05)。TDF组药物不良反应发生率低于ETV组,差异有统计学意义(P<0.05)。结论替诺福韦在促进乙型病毒性肝炎肝功能恢复中效果更佳,在替诺福韦长期用药过程中更应该积极检测肾功能的变化。
Objective To investigate the effect of entecavir and tenofovir in the treatment of hepatitis B and their influence on renal function. Methods A total of 50 patients with chronic hepatitis B admitted to Zhanjiang Central People’s Hospital from February 2017 to December 2019 were selected as the research objects and were divided into an entecavir(ETV) group and a tenofovir(TDF) group according to different treatment methods, with 25 cases in each group. Aspartate aminotransferase(AST), alanine aminotransferase(ALT), negative rate of hepatitis B virus(HBV)-DNA, serum creatinine(SCR), glomerular filtration rate(EGFR) and β_(2)-microglobulin(β_(2)-mg) were compared between the 2 groups. Results At the 6 th month of treatment, AST and ALT in TDF group were lower than those in ETV group, and the level of β_(2)-mg was higher than that in ETV group at the 3 rd and 6 th month of treatment,(P<0.05). There was no significant difference in HBV-DNA negative conversion rate and RBP level between the 2 groups at the 3 rd, 6 th and 12 th month after treatment(P>0.05). The incidence of adverse drug reactions in TDF group was lower than that in ETV group, the difference was statistically significant(P<0.05). Conclusion The effect of tenofovir in promoting the recovery of liver function in patients with hepatitis B is better, and the change of renal function should be actively detected in the long-term use of tenofovir.
作者
庞泽文
杨世春
PANG Ze-Wen;YANG Shi-Chun(Department of Pharmacy,Zhanjiang Central People's Hospital of Guangdong Province,Zhanjiang 524000,China)
出处
《中国药物经济学》
2021年第4期104-107,共4页
China Journal of Pharmaceutical Economics
